extreme rare mutations in lung cancer (ros1, trk, her2): treatment opportunities
Published 8 years ago • 2K plays • Length 18:41Download video MP4
Download video MP3
Similar videos
-
5:41
understanding nsclc treatments for less common mutations: alk, braf, ros1, her2, met
-
22:50
targeting her2, braf, kras, met, trk
-
2:47
how do doctors treat lung cancer with ros1 mutations?
-
0:40
what is a ros1 mutation in lung cancer?
-
21:10
targeting her2, braf, kras, met
-
0:41
treatment options for metastatic non-small cell lung cancer with no actionable mutations in 1l
-
1:41
what is a her2 mutation in lung cancer?
-
1:00
uncommon egfr mutations in metastatic non-small cell lung cancer.
-
2:37
how do doctors treat lung cancer with her2 mutations?
-
14:45
potential and progress in targeting less common markers: her2, braf, kras, met, trk, and ret
-
6:44
treatment options for lung cancer mutations & contingencies
-
2:11
identifying rare mutations in lung cancer
-
1:00
treatment options for metastatic non-small cell lung cancer with actionable mutations in 1l
-
1:16
ros1 mutations in lung cancer - lung cancer foundation of america
-
6:29
case based panel discussion nsclc – does a positive her2 mutation effect treatment decisions?
-
1:12
dr. yorio on t-dm1 in her2-mutant lung cancer treatment
-
23:10
egfr mutation positive tumors: treatment strategies in front line and at relapse
-
2:12
dr. drilon on entrectinib in patients with ros1-positive nsclc